Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
weizmannia coagulans SANK70258
- Development stage
- Preclinical
- Lead developer
- Mitsubishi Chemical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Weizmannia coagulans SANK70258 is a spore-forming, lactic acid-producing probiotic bacterium being investigated for various health benefits. As a live biotherapeutic, it modulates the gut microbiome and has direct immunomodulatory effects. Its spore-forming nature makes it resistant to heat and acid, allowing it to reach the intestine alive. Research has explored its potential in ulcerative colitis (UC) by enhancing the production of butyrate, an anti-inflammatory short-chain fatty acid, especially when combined with other specific bacteria. The bacterium is also being studied for its ability to relieve symptoms of upper respiratory tract infections, improve constipation, and enhance skin health. Many of the studies are authored by researchers from Mitsubishi Chemical Corporation, who manufacture the strain.
- Brand names
- Lacris-SLACRIS
- Other names
- Bacillus coagulans SANK 70258Heyndrickxia coagulans SANK70258
02
Targets
TLR2 (Toll-like Receptor 2)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on weizmannia coagulans SANK70258.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on weizmannia coagulans SANK70258.